endpts.com Open in urlscan Pro
108.138.36.96  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * Editorial Standards
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



November 15, 2023 07:00 AM ESTUpdated November 17, 12:46 PM
Financing
Manufacturing


EX­CLU­SIVE: NTX RAIS­ES $47.5M SE­RIES B TO COM­MER­CIAL­IZE PRO­TEIN, MR­NA
MAN­U­FAC­TUR­ING PLAT­FORMS 


ANNA BROWN

NEWS REPORTER

Ear­ly-stage bio­man­u­fac­tur­er Na­ture’s Tool­box (NTx) has col­lect­ed $47.5
mil­lion in a Se­ries B raise to bring its mR­NA and pro­tein pro­duc­tion
plat­forms to mar­ket, as well as to dou­ble its head­count and ex­pand its Rio
Ran­cho, NM fa­cil­i­ty.

NTx has two dif­fer­ent man­u­fac­tur­ing plat­forms: one called NTxscribe,
which pro­duces mR­NA, and the oth­er is named NTx­press, which is de­signed to
make pro­teins.

The Se­ries B is in­tend­ed to bring NTxscribe to mar­ket in the third quar­ter
of 2024, with a pro­to­type avail­able in the first half of next year, CEO Jamie
Cof­fin told End­points News in an in­ter­view. Mean­while, the pro­tein
plat­form is in ear­li­er stages of de­vel­op­ment, he not­ed.


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER


TRENDING NOW


FDA AP­PROVES VER­TEX AND CRISPR'S CAS­GEVY AS FIRST CRISPR-EDIT­ED THER­A­PY
FOR BE­TA-THA­LASSEMIA


HOW PHAR­MA GI­ANTS LIKE GSK AND BRIS­TOL MY­ERS ARE US­ING TECH TO SHAPE THEIR
FU­TURE


NO­VO NORDISK RESTARTS AD­VER­TIS­ING FOR OBE­SI­TY DRUG WE­GOVY WITH NEW
CAM­PAIGN


AM­I­CUS BRIEFS FLY IN AS IRA 'FAIR PRICE' DEAD­LINE LOOMS


A DECADE AF­TER ITS FIRST FDA AP­PROVAL, TAKE­DA EX­PANDS LA­BEL OF HYQVIA TO
IN­CLUDE RARE AU­TOIM­MUNE DIS­OR­DER

sponsored


BIOTECH: A NEW PATH TO CAP­I­TAL RAIS­ING IN PUB­LIC AND PRI­VATE MAR­KETS

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * Editorial Standards
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2024

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET



BREAKING NEWS ALERTS 2-3 times a week


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.